This statistic shows the top products of biopharmaceutical company Gilead Sciences from 2022 to 2024, based on revenue. Gilead Sciences Inc. is headquartered in California and is specialized in discovering, developing and commercializing therapeutics. In 2024, Gilead Sciences' COVID-19 treatment Veklury (remdesivir) generated some 1.8 billion U.S. dollars in revenue, a significant decrease compared to 5.6 billion in 2021.
Leading products of Gilead Sciences from 2022 to 2024 based on revenue
(in million U.S. dollars)
Adjust the presentation of the statistic and data points.
Share the statistic on social media channels or embed the statistic in your
website using "Embed Code", where available.
Cite this statistic and select one of the following formats: APA, Chicago, Harvard, MLA & Bluebook.
The statistic is available in another language. Switch language.
Print the statistic including description and metadata.
Chart type
Leading products of Gilead Sciences from 2022 to 2024 based on revenue
Share this statistic
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
* Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).
Statista has been my savior on several occasions.
The site is easy to maneuver and the data is in a format that can
go right into a report or presentation.
Learn more about how Statista can support your business.
Gilead Sciences, & U.S. Securities and Exchange Commission. (February 26, 2025). Leading products of Gilead Sciences from 2022 to 2024 based on revenue (in million U.S. dollars) [Graph]. In Statista. Retrieved April 26, 2025, from https://www.statista.com/statistics/274509/top-products-of-gilead-sciences-based-on-revenue/
Gilead Sciences, und U.S. Securities and Exchange Commission. "Leading products of Gilead Sciences from 2022 to 2024 based on revenue (in million U.S. dollars)." Chart. February 26, 2025. Statista. Accessed April 26, 2025. https://www.statista.com/statistics/274509/top-products-of-gilead-sciences-based-on-revenue/
Gilead Sciences, U.S. Securities and Exchange Commission. (2025). Leading products of Gilead Sciences from 2022 to 2024 based on revenue (in million U.S. dollars). Statista. Statista Inc.. Accessed: April 26, 2025. https://www.statista.com/statistics/274509/top-products-of-gilead-sciences-based-on-revenue/
Gilead Sciences, and U.S. Securities and Exchange Commission. "Leading Products of Gilead Sciences from 2022 to 2024 Based on Revenue (in Million U.S. Dollars)." Statista, Statista Inc., 26 Feb 2025, https://www.statista.com/statistics/274509/top-products-of-gilead-sciences-based-on-revenue/
Gilead Sciences & U.S. Securities and Exchange Commission, Leading products of Gilead Sciences from 2022 to 2024 based on revenue (in million U.S. dollars) Statista, https://www.statista.com/statistics/274509/top-products-of-gilead-sciences-based-on-revenue/ (last visited April 26, 2025)
Leading products of Gilead Sciences from 2022 to 2024 based on revenue (in million U.S. dollars) [Graph], Gilead Sciences, & U.S. Securities and Exchange Commission, February 26, 2025. [Online]. Available: https://www.statista.com/statistics/274509/top-products-of-gilead-sciences-based-on-revenue/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
